Genomic approaches to understanding response and resistance to immunotherapy

Clinical Cancer Research

Volumn 22, Issue 23, 2016, Pages 5642-5650

  Braun, David A ^a,b   Burke, Kelly P ^a   Van Allen, Eliezer M ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TICILIMUMAB; TRANSCRIPTOME;

CANCER IMMUNOTHERAPY; CELL GROWTH; GENETIC RESISTANCE; GENOME ANALYSIS; GENOMICS; GERMLINE MUTATION; HUMAN; IMMUNE EVASION; IMMUNOSURVEILLANCE; MELANOMA; MUTATIONAL ANALYSIS; MUTATIONAL LOAD; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; SOMATIC MUTATION; TRANSCRIPTOMICS; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR RESISTANCE; UPREGULATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MUTATION; NEOPLASM; PROCEDURES;

ANIMALS; DRUG RESISTANCE, NEOPLASM; GENOMICS; HUMANS; IMMUNOTHERAPY; MUTATION; NEOPLASMS; TRANSCRIPTOME;

EID: 85006253066     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0066     Document Type: Review

References (75)

1. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014; 192:5451-8.
2. Rosenberg SA, Restifo NP, Yang J.C., Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308.
3. Gill S, June CH Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 2015; 263:68-89.
4. Hacohen N, Fritsch EF, Carter T.A., Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res 2013; 1:11-5.
5. Leach DR, Krummel MF, Allison JP Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-6.
6. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366:2517-9.
7. Sharma P, Allison JP The future of immune checkpoint therapy. Science 2015; 348:56-61.
8. Hodi FS, O'Day SJ, McDermott DF, Weber R.W., Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumabinpatients with metastatic melanoma. N Engl J Med 2010; 363:711-23.
9. Schadendorf D, Hodi FS, Robert C, Weber J.S., Margolin K., Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33:1889-94.
10. Larkin J, Chiarion-Sileni V, Gonzalez R., Grob JJ, Cowey CL, Lao CD, et al Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34.
11. Topalian SL, Hodi FS, Brahmer J.R., Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54.
12. Ansell SM, Lesokhin AM, Borrello I, Halwani A., Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-9.
13. Borghaei H, Paz-Ares L, Horn L., Spigel DR, Steins M, Ready NE, et al Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373:1627-39.
14. Herbst RS, Baas P, Kim D.W., Felip E., Perez-Gracia JL, Han JY, et al Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387:1540-50.
15. Postow MA, Chesney J, Pavlick A.C., Robert C., Grossmann K, McDermott D, et al Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-17.
16. Robert C, Long GV, Brady B, Dutriaux C., Maio M, Mortier L, et al Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30.
17. Robert C, Schachter J, Long G.V., Arance A., Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521-32.
18. Rosenberg JE, Hoffman-Censits J, Powles T., van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909-20.
19. Seiwert TY, Burtness B, Mehra R., Weiss J, Berger R, Eder J.P., et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an openlabel, multicentre, phase 1b trial. Lancet Oncol 2016; 17:956-65.
20. Alexandrov LB, Nik-Zainal S, Wedge D.C., Aparicio SA, Behjati S, Biankin AV, et al Signatures of mutational processes in human cancer. Nature 2013; 500:415-21.
21. Snyder A, Makarov V, Merghoub T., Yuan J, Zaretsky JM, Desrichard A, et al Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-99.
22. Van Allen E.M., Miao D, Schilling B., Shukla SA, Blank C, Zimmer L, et al Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350:207-11.
23. Fritsch EF, Rajasagi M, Ott P.A., Brusic V., Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res 2014; 2:522-9.
24. Hugo W, Zaretsky JM, Sun L, Song C., Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016; 165:35-44.
25. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P., Makarov V, Havel JJ, et al Cancer immunology. Mutational landscape determines sensitivity toPD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8.
26. Le DT, Uram JN, Wang H, Bartlett B.R., Kemberling H., Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509-20.
27. Gerlinger M, Rowan AJ, Horswell S, Larkin J., Endesfelder D, Gronroos E, et al Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-92.
28. McGranahan N, Furness AJ, Rosenthal R, Ramskov S., Lyngaa R, Saini SK, et al Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351:1463-9.
29. Diaz LA, Uram JN, Wang H, Bartlett B., Kemberling H, Eyring A, et al Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. J Clin Oncol 34, 2016 (suppl; abstr 3003).
30. Kelderman S, Schumacher TN, Kvistborg P. Mismatch repair-deficient cancers are targets for anti-PD-1 therapy. Cancer Cell 2015; 28:11-3.
31. Hiniker SM, Chen DS, Knox SJ Abscopal effectinapatientwith melanoma. N Engl J Med 2012; 366:2035.
32. Postow MA, Callahan MK, Barker C.A., Yamada Y., Yuan J, Kitano S, et al Immunologic correlates of the abscopal effect in apatient with melanoma. N Engl J Med 2012; 366:925-31.
33. Crittenden M, Kohrt H, Levy R., Jones J, Camphausen K, Dicker A., et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol 2015; 25:54-64.
34. Everson RG, Antonios JP, Lisiero D.N., Soto H., Scharnweber R, Garrett MC, et al Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro Oncol 2016; 18:368-78.
35. Gang AO, Frosig TM, Brimnes M.K., Lyngaa R., Treppendahl MB, Gronbaek K, et al. 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer J 2014; 4:e197.
36. Smyth MJ, Ngiow SF, Ribas A, Teng MW Combination cancer immunotherapies tailoredtothe tumour microenvironment. Nat Rev Clin Oncol 2016; 13:143-58.
37. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10.
38. Tumeh PC, Harview CL, Yearley J.H., Shintaku IP, Taylor EJ, Robert L, et al PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71.
39. Van Allen E.M., Golay HG, Liu Y, Koyama S., Wong K, Taylor-Weiner A, et al. Long-term benefit of PD-L1 blockade in lung cancer associated with JAK3 activation. Cancer Immunol Res 2015; 3:855-63.
40. Rajasagi M, Shukla SA, Fritsch E.F., Keskin DB, De Luca D, Carmona E, et al Systematic identificationofpersonal tumor-specific neoantigensin chronic lymphocytic leukemia. Blood 2014; 124:453-62.
41. Kranz LM, Diken M, Haas H., Kreiter S, Loquai C, Reuter K.C., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016; 534:396-401.
42. Rooney MS, Shukla SA, Wu C.J., Getz G., Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160:48-61.
43. Herbst RS, Soria JC, Kowanetz M, Fine G.D., Hamid O., Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7.
44. Tirosh I, Izar B, Prakadan S.M., Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016; 352:189-96.
45. Lee SJ, Jang BC, Lee S.W., Yang YI, Suh SI, Park YM, et al Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006; 580:755-62.
46. Green MR, Monti S, Rodig S.J., Juszczynski P., Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116:3268-77.
47. Topalian SL, Drake CG, Pardoll DM Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27: 450-61.
48. Koyama S, Akbay EA, Li Y.Y., Herter-Sprie GS, Buczkowski KA, Richards W.G., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 2016; 7: 10501.
49. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013; 31:1806-14.
50. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012; 18:5329-40.
51. Spranger S, Bao R, Gajewski TF Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015; 523:231-5.
52. Parsa AT, Waldron JS, Panner A, Crane C.A., Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13:84-8.
53. Atefi M, Avramis E, Lassen A., Wong DJ, Robert L, Foulad D, et al Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014; 20:3446-57.
54. Peng W, Chen JQ, Liu C, Malu S., Creasy C, Tetzlaff MT, et al Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2016; 6:202-16.
55. Kataoka K, Shiraishi Y, Takeda Y., Sakata S, Matsumoto M, Nagano S., et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 2016; 534:402-6.
56. Lawrence MS, Stojanov P, Mermel C.H., Robinson JT, Garraway LA, Golub TR, et al Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505:495-501.
57. Wang C, Krishnakumar S, Wilhelmy J., Babrzadeh F, Stepanyan L, Su L.F., et al. High-throughput, high-fidelity HLA genotyping with deep sequencing. Proc Natl Acad Sci U S A 2012; 109:8676-81.
58. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 1999; 401:921-3.
59. Shukla SA, Rooney MS, Rajasagi M, Tiao G., Dixon PM, Lawrence MS, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol 2015; 33:1152-8.
60. Zaretsky JM, Garcia-Diaz A, Shin D.S., Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016; 375:819-29.
61. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J., Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88:100-8.
62. Sucker A, Zhao F, Real B., Heeke C, Bielefeld N, Maben S., et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res 2014; 20:6593-604.
63. Champiat S, Lambotte O, Barreau E., Belkhir R, Berdelou A, Carbonnel F., et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27:559-74.
64. Horvat TZ, Adel NG, Dang T.O., Momtaz P., Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 2015; 33:3193-8.
65. Naidoo J, Page DB, Li B.T., Connell LC, Schindler K, Lacouture ME, et al Toxicities of the anti-PD-1 and anti-PD-L1 immunecheckpoint antibodies. Ann Oncol 2015; 26:2375-91.
66. Nielsen M, Lundegaard C, Blicher T., Lamberth K, Harndahl M, Justesen S., et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and - B locus protein of known sequence. PLoS One 2007; 2:e796.
67. Lundegaard C, Lamberth K, Harndahl M., Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008; 36:W509-12.
68. Peters B, Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005; 6:132.
69. Gubin MM, Zhang X, Schuster H., Caron E, Ward JP, Noguchi T, et al Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577-81.
70. Yadav M, Jhunjhunwala S, Phung Q.T., Lupardus P., Tanguay J, Bumbaca S, et al Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515:572-6.
71. Robbins PF, Lu YC, El-Gamil M, Li Y.F., Gross C., Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19: 747-52.
72. van Rooij N., van Buuren MM, Philips D, Velds A, Toebes M., Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013; 31: e439-42.
73. Calis JJ, Maybeno M, Greenbaum J.A., Weiskopf D., De Silva AD, Sette A, et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol 2013; 9:e1003266.
74. Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis J.J., et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2015; 21: 81-5.
75. Schumacher T, Bunse L, Pusch S., Sahm F, Wiestler B, Quandt J., et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; 512:324-7.